Chapter 3.4. Combination of Inhaled Corticosteroids and Long-Acting β2-Agonists in Chronic Obstructive Pulmonary Disease

  1. Peter G. Gibson1,
  2. Michael Abramson2,
  3. Richard Wood-Baker3,
  4. Jimmy Volmink4,
  5. Michael Hensley5 and
  6. Ulrich Costabel6
  1. Paul W Jones

Published Online: 25 OCT 2007

DOI: 10.1002/9780470987377.ch21

Evidence-based Respiratory Medicine

Evidence-based Respiratory Medicine

How to Cite

Jones, P. W. (2005) Combination of Inhaled Corticosteroids and Long-Acting β2-Agonists in Chronic Obstructive Pulmonary Disease, in Evidence-based Respiratory Medicine (eds P. G. Gibson, M. Abramson, R. Wood-Baker, J. Volmink, M. Hensley and U. Costabel), Blackwell Publishing Ltd, Oxford, UK. doi: 10.1002/9780470987377.ch21

Editor Information

  1. 1

    John Hunter Hospital, Newcastle, New South Wales, Australia

  2. 2

    Monash University, Central & Eastern Clinical School, The Alfred, Melbourne, Victoria, Australia

  3. 3

    University of Tasmania, Hobart, Tasmania, Australia

  4. 4

    University of Cape Town, Cape Town, South Africa

  5. 5

    University of Newcastle, Newcastle, New South Wales, Australia

  6. 6

    Ruhrlandklinik, Essen, Germany

Publication History

  1. Published Online: 25 OCT 2007
  2. Published Print: 22 NOV 2005

ISBN Information

Print ISBN: 9780727916051

Online ISBN: 9780470987377

SEARCH

Keywords:

  • long-acting B2-agonists;
  • inhaled corticosteroids;
  • chronic obstructive pulmonary disease therapy;
  • clinical trials;
  • breathlessness

Summary

This chapter contains sections titled:

  • Background

  • Clinical trials in COPD

  • FEV1

  • Exacerbations

  • Health status and breathlessness

  • Abridged abstract of the Cochrane Review21

  • Conclusions

  • Author's statement